Journal
AGING-US
Volume 11, Issue 11, Pages 3505-3522Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/aging.101993
Keywords
Nampt; mesenchymal stem cells (MSC); senescence; NAD(+); Sirt1; regenerative medicine
Categories
Funding
- National Natural Science Foundation of China [81571370]
- Jilin Province Science and Technology Development Projects [20150414029GH, 20130101130JC]
- Norman Bethune Program of Jilin University [2012204]
- Science and Technology Projects of the Education Department of Jilin Province [JJKH20190007KJ]
Ask authors/readers for more resources
In vitro replicative senescence affects MSC characteristics and functionality, thus severely restricting their application in regenerative medicine and MSC-based therapies. Previously, we found that MSC natural senescence is accompanied by altered intracellular nicotinamide adenine dinucleotide (NAD(+)) metabolism, in which Nampt plays a key role. However, whether Nampt influences MSC replicative senescence is still unclear. Our study showed that Nampt expression is down-regulated during MSC replicative senescence. Nampt depletion via a specific Nampt inhibitor FK866 or Nampt knockdown in early passage MSCs led to enhanced senescence as indicated by senescence-like morphology, reduced proliferation, and adipogenic and osteogenic differentiation, and increased senescence-associated-beta-galactosidase activity and the expression of the senescence-associated factor p16(INK4a). Conversely, Nampt overexpression ameliorated senescence-associated phenotypic features in late passage MSCs. Further, Nampt inhibition resulted in reduced intracellular NAD(+) content, NAD(+)/NADH ratio, and Sirt1 activity, whereas overexpression had the opposite effects. Exogenous intermediates involved in NAD(+) biosynthesis not only rescued replicative senescent MSCs but also alleviated FK866-induced MSC senescence. Thus, Nampt suppresses MSC senescence via mediating NAD(+)-Sirt1 signaling. This study provides novel mechanistic insights into MSC replicative senescence and a promising strategy for the severe shortage of cells for MSC-based therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available